

20th February 2025

- | | |
|--|--|
| <p>(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Dear Sir / Madam,

Sub: USFDA inspection at facility of Sitec in Mahape, Navi Mumbai, India

Pursuant to provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that United States Food and Drugs Administration ('USFDA') has conducted a current Good Manufacturing Practices ('cGMP') inspection at the analytical testing facility of Sitec Labs Limited, wholly owned subsidiary of the Company ('Sitec') located in Mahape, Navi Mumbai from 18th to 20th February, 2025.

On conclusion of the inspection, Sitec received 2 (two) observations in Form 483. The Company will work closely with the USFDA and remains committed to address these observations comprehensively within stipulated time.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Muskan Jain